Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Giant Cell Tumor of Bone × Denosumab × Clear all

Phase

Phase 4 2 Phase 3 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 8 Neoplasm Metastasis 4 Multiple Myeloma 4 Neoplasms 3 Kidney Neoplasms 3 Smoldering Multiple Myeloma 2 Prostatic Neoplasms 2 Lung Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Thyroid Neoplasms 1 Thyroid Cancer Metastatic 1 Parathyroid Neoplasms 1 Osteosarcoma 1 Osteoblastoma 1 Neoplastic Cells, Circulating 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Inflammatory Breast Neoplasms 1 Hypercalcemia 1 Humoral Hypercalcemia Of Malignancy 1 Hodgkin Disease 1 Head and Neck Neoplasms 1 Granuloma, Giant Cell 1 Giant Cell Tumor of Bone 1 Endocrine Gland Neoplasms 1 Colorectal Neoplasms 1

Interventions

gentamicin-polymethylmethacrylate bead 1 fludarabine 1 aldesleukin 1 Nivolumab 1 Ipilimumab 1 Denosumab 1 Dasatinib 1 Cyclophosphamide 1 CTLA-4 Antigen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03620149 2021-01-06

REDUCE

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Terminated

Giant Cell Tumor of Bone

Data powered by HemOnc (CC BY 4.0) Colophon ⚡